Cargando…

A B‐Raf V600E gene signature for melanoma predicts prognosis and reveals sensitivity to targeted therapies

BACKGROUND: B‐Raf V600E mutations account for about half of all skin cutaneous melanoma cases, and patients with this mutation are sensitive to BRAF inhibitors. However, aberrations in other genes in the MAPK/ERK pathway may cascade a similar effect as B‐Raf V600E mutations, rendering those patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Kevin, Zhou, Emily, Cheng, Chao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855909/
https://www.ncbi.nlm.nih.gov/pubmed/35044091
http://dx.doi.org/10.1002/cam4.4491